Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
- Conditions
- Vascular Access Complication
- Interventions
- Device: AccuCath 2.25" BC Intravascular Catheter
- Registration Number
- NCT02449798
- Lead Sponsor
- C. R. Bard
- Brief Summary
Study objective is to evaluate user preference, time for procedure, insertion success rates, complications, completion of therapy and dwell time of the AccuCath 2.25" BC device placed in difficult IV access patients in the emergency department.
- Detailed Description
A one arm, prospective feasibility study using the AccuCath 2.25" BC Intravascular Catheter System placed in the upper arm with ultrasound guidance, and the lower arm with and without ultrasound guidance based on clinical assessment. Subjects will be subjected to a maximum of 4 attempts. If unsuccessful by the 4th attempt, alternatives will be considered as per current standard of care.
Currently multiple IV attempts are made in difficult IV access patients without success. Patients are often escalated to more invasive lines due to the need for longer catheters without clinical indication. The study will evaluate the feasibility of AccuCath 2.25" BC as a low risk, lower cost alternative for this patient population in lieu of using a midline, peripherally inserted central line or central venous catheter when not clinically required for purposes of therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
- Male or female, age > 18 years old;
- Capable and willing to give informed consent;
- English speaking;
- Acceptable candidate for an elective, non-emergent peripheral IV as determined by ordering physician;
- Admitted to inpatient area for minimum of 24 hours, preferably for average hospital length of stay;
- Difficult venous access patient as defined by either 2 failed initial attempts without ultrasound guidance or a history of difficult access plus the inability to directly visualize or palpate a target vein.
- Male or female, < 18 years old;
- Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
- Previous venous grafts or surgery at the target vessel access site;
- Subjects with lymphedema or status-post mastectomy on affected side;
- Currently involved in other investigational clinical trials (unless permission is granted by other study PI).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AccuCath 2.25" BC Intravascular Catheter AccuCath 2.25" BC Intravascular Catheter Use of AccuCath 2.25" BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins.
- Primary Outcome Measures
Name Time Method Number of Catheter Attempts Required to Complete Successful PIV Placement At IV insertion attempt, generally from 3-15 minutes First Attempt Success Rate At initial IV insertion attempt, generally from 3-15 minutes
- Secondary Outcome Measures
Name Time Method Dwell Time Duration of IV dwell from initial insertion success through IV removal, usually ranges from 0-336 hours (0-14 days) but could be up to 696 hours (29 days) IV dwell time in hours until IV is no longer needed or complicates.
Completion of Therapy During IV dwell from initial insertion success through IV removal, usually ranges from 7-14 days but could be up to 29 days Count of whether the catheter lasted for the duration of intended therapy without complication requiring early removal.
Time to Catheter Placement At initial IV insertion attempt through successful cannulation, generally from 3-15 minutes Time will be measured from initial vessel insertion through successful cannulation
Complications During IV dwell from initial insertion success through IV removal, usually ranges from 7-14 days but could be up to 29 days Count of IV complications that require IV removal before completion of therapy. Includes infiltration, extravasation, phlebitis, occlusion, dislodgement, infection, leaking at site, pain at site
Patient Satisfaction at IV removal, which can be up to a maximum of 29 days A 5-point Likert scale (1-5) was used for measurement of satisfaction with overall IV performance at IV removal. A score of 1 indicated the lowest satisfaction, while a score of 5 indicated the highest satisfaction. A score of 3-5 was considered positive.
Trial Locations
- Locations (1)
North Shore - Long Island Jewish Health System
🇺🇸Manhasset, New York, United States